> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Variable Clinical Pharmacology Studies for Peptides Needed: Merck
- URL: https://www.fdaweb.com/variable-clinical-pharmacology-studies-for-peptides-needed-merck/
- Published: 2021-07-13T12:00:00.000Z
- Updated: 2026-09-14T17:05:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149694

Commenting on an FDA request for information and comments on evaluating the clinical pharmacology of peptides, Merck says its experience is there are few instances in which a one-size-fits-all-type requirement for clinical pharmacology studies would be appropriate. In its [response](https://downloads.regulations.gov/FDA-2021-N-0347-0005/attachment%5F1.pdf?ref=fdaweb.com), the company says that due to the unique characteristics of each product, different assessments (e.g., hepatic insufficiency, drug-dug interaction, immunogenicity, or thorough QT studies) would be more or less useful to understand the clinical profile of a given product.